What are the recommended pharmacological treatments for managing symptoms in patients with emphysema?

Pharmacological treatment for managing symptoms in patients with emphysema, a form of COPD, primarily involves inhaled bronchodilators. Initially, short-acting bronchodilators such as short-acting beta2 agonists (SABA) and short-acting muscarinic antagonists (SAMA) are used as needed to relieve breathlessness and exercise limitation.

For patients who remain breathless or have exacerbations despite using short-acting bronchodilators, long-acting bronchodilator combinations are recommended. Specifically, a combination of long-acting muscarinic antagonists (LAMA) and long-acting beta2 agonists (LABA) should be offered if the patient does not have asthmatic features or steroid responsiveness.

Inhaled corticosteroids (ICS) are not routinely recommended based on reversibility tests and should be used cautiously due to potential side effects, including pneumonia. Their use is generally reserved for patients with features suggesting steroid responsiveness or frequent exacerbations.

Additionally, patients at risk of exacerbations may be offered a short course of oral corticosteroids and antibiotics as part of an exacerbation action plan.

Smoking cessation support, vaccinations, and non-pharmacological interventions such as pulmonary rehabilitation are also critical components of management but are outside the scope of pharmacological treatment.

Medications such as bosentan, losartan, nifedipine, nitric oxide, pentoxifylline, phosphodiesterase-5 inhibitors, and statins are not recommended solely for managing pulmonary hypertension caused by COPD, and certain drugs like alpha-blockers, ACE inhibitors, calcium channel blockers, and digoxin (unless atrial fibrillation is present) should be avoided for cor pulmonale related to COPD.

Overall, the pharmacological approach focuses on bronchodilation to relieve symptoms and reduce exacerbations, tailored to the patient's symptom burden and exacerbation risk.

References: ¹